

THANK YOU

Cosmopolitan Foundation Canada Inc.



Alberta Diabetes
FOUNDATION

THANK YOU

Dear Cosmopolitan Friends,

On behalf of the Alberta Diabetes Foundation, I want to extend my sincere thanks to you for your ongoing support and dedication towards diabetes research in Alberta.

It has been such a privilege to work with the CFCI through our partnership and be a part of the Cosmopolitan Club's international mandate of fighting diabetes. In the last 12 months, your investment has furthered the impact of Dr Jean Buteau, who is expecting to be starting the clinical trial in the third quarter of 2024. As you can imagine the process of moving research into clinical trials is a long one. Between meetings with the clinical trials office at the UofA, pharmaceutical protocols and approvals to sourcing the drugs and receiving Health Canada approval, the road is long but we appreciate your willingness to come along the journey with us. Your support has been instrumental in getting us to where we are at and will ensure this clinical trial moves forward.

Thank you for your steadfast support and devotion to the Alberta Diabetes Foundation and the work of Dr. Jean Buteau. I am excited to continue to share updates with you on the progress of this work.

Thank you again to the entire club and its community for your support.

Warm regards,



Lindsay Burnham
Executive Director
Alberta Diabetes Foundation

Lindsay Burnham

Diabetes is Relentless, but together so are we!

YOUR IMPACT


BETA CELL REGENERATION PROJECT

Clinical Researcher Lead: Dr. Jean Buteau

Clinical Lead: Dr. Peter Senior

This project is testing an oral drug to treat and potentially cure type 1 diabetes. Essentially what this means is that, if successful, it can reverse the course of type 1 diabetes. By taking an oral pill, people with diabetes would once again be able to produce insulin on their own.

Dr Jean Buteau, who has been preparing for a phase 1a clinical trial, which would involve testing the drug, Tolimidone, in 12 patients is now preparing to start clinical trials in the third quarter of 2024.. This is truly a significant milestone; it is rare for a drug candidate studied in labs within the Alberta Diabetes Institute to make it to clinical trials. Thanks to your support, we are excited to make this leap into human trials. Dr. Peter Senior has sat down with the clinical trials office at the UofA to ensure everything is in place to move this forward to a human trial. Many documents and processes are needed to create a clinical trial, which includes an approved protocol, which is a document that describes how a clinical trial will be conducted. Dr. Buteau and Dr. Senior have been working with BioDex Pharmaceuticals, based in Cardiff, UK. and they are very enthusiastic to get this trial off the ground. Once the protocol is approved, Peter and Jean can officially put their application forward to Health Canada (anticipating to do this the first quarter of 2024) and would be looking to start the trial the third quarter of 2024.



"Very often we feel isolated in our lab, so knowing that we have support from the community is truly a huge motivation factor in the work that we do." -Dr. Jean Buteau

Lindsay Burnham, CFRE
Executive Director- Alberta Diabetes Foundation

Email: executivedirector@abdiabetes.com

Office: 780-492-8652 | Cell: 780-271-7592 | Toll Free 1.800.563.2450

1-020 Li Ka Shing Centre | University of Alberta
Edmonton AB T6G 2E1

www.AlbertaDiabetesFoundation.com



Alberta Diabetes
FOUNDATION